Dr. Lee is a veteran biotech executive with over a decade of experience leading cell and gene therapy programs for human applications. Currently serving as the CSO at Senti Biosciences, Dr. Lee leads the company’s effort to leverage Senti’s gene circuits and synthetic biology platform for the development of next generation CAR-NK therapeutics for difficult-to-treat cancer indications. Previously as VP of Cell Therapy at Sangamo Therapeutics, Dr. Lee led the company’s programs around T-cell engineering, including CAR-T cell therapies for oncology applications (a platform recently licensed to Kite, a Gilead company) and T-cell therapies for HIV. Dr. Lee also served as the head of Sangamo’s immunology/Treg therapeutic pipeline. Dr. Lee received his B.S. in Chemical Engineering from California Institute of Technology and his Ph.D. in Chemical Engineering from U.C. Berkeley.